Vulva Cancer

The EORTC vulva cancer module is developed as a disease and treatment specific questionnaire module for vulva cancer patients to supplement the EORTC QLQ-C30. The aim of the study is to test the scale structure, reliability, and validity of the EORTC VU34 in patients diagnosed with vulva cancer at different stages of disease and with different treatment modalities.We aim to develop a questionnaire module that will allow broad international cross-cultural and cross-country adaptation which can be used in clinical trials.

The three first phases of development and validation is completed. The questionnaire is now undergoing formal field testing with psychometric analyses to ensure it works as intended.
We have now recruited a sufficient number of patients and will close recruitment after this coming meeting.

Current status:

Phase 4, recruitment ends at the end of September 2025

Analyses will start during autumn 2025 once all legal permission to transfer data has been obtained.

The first meeting with statistician has been held and a statistical anlaysis plan (SAP) has been agreed on .

The EORTC vulva cancer module is a questionnaire developed in collaboration with patients with cancer in their outer genitals (vulva cancer). To make sure the questionnaire works as intended we need to test it in women from different countries and cultures, with different disease stages and who have undergone different treatments. This will allow us to use the questionnaire in the clinic and in future studies.